Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection
Guerbet SA:Receives approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol (ethiodized oil) Injection, in Montreal, Canada.FDA approval provides clinicians with additional resource for patient care management.Says it has acquired the Ethiodol NDA effective May 7, 2010 and since then has been working with the FDA to resume manufacturing of Ethiodol to ensure continued availability for the U.S. patients.
Latest Developments for Guerbet SA
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Guerbet launches CE-marked FlowSens solution on global markets
- Guerbet SA's Lipiodol approved for reimbursement in Japan when used for Transcatheter Arterial Chemo-embolization
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this